The Global Grand Mal Seizures Market is expected to reach US$ 2.8 billion by 2023, and the market is projected to grow at a CAGR of ~ 4.2 % during the forecast period 2017-2023.
Epilepsy is a group of neurological disorders characterized by brief, involuntary episodes of vigorous shaking of a part or complete body. The patient may experience loss or disturbance of consciousness and movements along with sensory or psychiatric disturbances. About 24 million people around the globe had epilepsy in 2015 across the globe. Grand mal seizures or tonic–clonic seizures are a type of generalized seizures, which affect the entire brain and are the most common type of epileptic seizures. Grand mal seizures are caused by neurotransmitter imbalances, which can also be influenced by fatigue, lack of sleep, hypertension, stress, intense lighting, rapid motion, blood sugar level, anxiety, etc. The Global Grand Mal Seizures Market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa. The grand mal seizures consist of two phases, the tonic phase and the clonic phase. The tonic phase involves loss of consciousness and muscle twitching and the phase usually last only for a few seconds. The clonic phase consists of rapid muscle contraction and relaxation resulting in convulsions.
Get a Sample Report @ https://www.marketresearchfuture.com/sample_request/4087 .
Development of better tolerated third generation drugs, increasing screening of patients, and growing geriatric population- they are more susceptible to epilepsy- drive the growth of the market. Increased patent expiry for a number of anti-epilepsy drugs such as Neurontin (2003) and Lyrica (scheduled in 2018), unknown origin and action mechanism of epilepsy, and concurrent lack of innovative drugs are likely to affect the market growth negatively. The market is also constrained by the poor efficacy and efficiency of most of the anti-epileptic drugs. A sizeable segment of patients respond very poorly or none at all to main line drugs such as the Gamma Aminobutyric Acid Modulators and ion channel blockers. These drugs have serious adverse effect on the patient such as depression, and suicidal behaviour, dizziness, fatigue, weight gain, etc. Social stigma associated with the epilepsy, especially, in the developing countries may hamper the market over the forecast period.
Top key Players of Grand Mal Seizure Market:
Some of key players profiled in the report are Pfizer, Inc., Johnson & Johnson Services Inc., UCB Celltech, Abbott Laboratories, GlaxoSmithKline plc. Novartis AG, Sanofi, Shire Pharmaceuticals Limited, and Teva Pharmaceutical Industries.
The Americas accounts for the significant market share owing to extensive use of medications and greater expenditure on the health care. Additionally, the fastest uptake of new technology and drugs in the US drives the global Grand Mal Seizures Industry. The concentration of the major medical diagnostic device manufacturers in the developed regions is also adding fuel to the market. Europe is the second largest market due to a high disposable income and rising awareness about the grand mal seizures. Asia Pacific region is expected to grow rapidly and China and India are likely to lead the market during the forecast period.
Gulf nations, Saudi Arabia and the UAE, drive the Middle East & African market. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development.
- Research Methodology
- Market dynamics
- Market factor analysis
- Global Grand Mal Seizure Market, by Drug Generation
- Global Grand Mal Seizure Market, by Drug Class
- Global Grand Mal Seizure Market, by Surgery
- Global Grand Mal Seizure Market, by End Users
- Global Grand Mal Seizure Market, by Region
- Competitive landscape
- Company profile
Ask to Expert @ https://www.marketresearchfuture.com/enquiry/4087 .
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
+1 646 845 9312